semaglutide treatments In Portland, OR GLP-1s | AgelessRx

#Healthcare #MedTech #HealthInnovation #DoctorsOfLinkedIn #HealthIT To view or add a comment, sign in Phase 3 TRANSCEND: Setmelanotide achieved a 16.5% reduction in BMI over 52 weeks by directly activating MC4R and bypassing impaired leptinPOMC signalingmarking a significant advance for patients with acquired hypothalamic obesity

These include the following

Progress builds steadily over time

There is no FDA-approved generic version of semaglutide available on the market

Insulin glargine had similar effectiveness as either once- or twice-daily NPH insulin in reducing HbA1c and fasting glucose (Table 11) with a similar incidence of hypoglycemia [see Adverse Reactions (6.1)]

The Lipo-Mino-Mix-C version adds L-Carnitine for enhanced fat burning